FDA
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Announces American Journal of Gastroenterology Publishes Full Results from Positive LINZESS Phase IIIb Trial in Adults with IBS-C
-
-
-
-
-
-
-
AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer
-
251,959 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All